Biology Methods and Protocols

Comparison of Cardiometabolic Benefits and Tolerability in Patients on Sustained Low Doses of Semaglutide or Tirzepatide

At a glance

Weight loss and recorded adverse-event patterns differed between agents.

The research question

What outcomes accompany sustained initiation-dose prescribing?

Overview

The study examined sustained prescribing at initiation doses in routine care.

Study design & methods

Federated EHR criteria identified 814 patients repeatedly prescribed semaglutide 0.25 mg and 1,016 prescribed tirzepatide 2.5 mg over at least six months. Matched analyses used clinical-note curation.

Principal findings

Twelve-month weight changes were −5.5% with tirzepatide versus −2.2% with semaglutide. Tirzepatide had higher recorded constipation and acute kidney injury rates over twenty-four months.

Limitations & interpretation

Observational prescription patterns do not confirm ingestion, intentional microdosing or causal treatment effects. Selection, access, tolerability and residual confounding may influence comparisons; prospective validation is needed.

Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.

Keep exploring.

All publications
CardiometabolismPreprint - Submitted for Peer-Review

Excessive Weight Loss with Zepbound Is Associated with Higher Rates of Adverse Events, Electrolyte Imbalances, and Hospitalization than Moderate Weight Loss

While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.

Preprints.org
October 21, 2026
CardiometabolismConference

Menopause Hormone Therapy and Weight Loss Response to GLP-1–Based Therapies in Midlife Women: A Retrospective Cohort Study

In this large real-world cohort of midlife women treated for overweight or obesity, concomitant HT was associated with significantly greater and sustained weight loss with SEM. A similar directional effect with TZP was observed at early timepoints but did not reach statistical significance. Larger prospective studies are warranted to confirm these observations and to inform individualized treatment strategies in midlife women.

The Menopause Society — 2026 Annual Meeting
October 20, 2026
Your next question could change everything.

What will you
discover next?

Let’s find out
Ideas are connected. Your next discovery starts here.